EXACT Sciences Corporation  

(Public, NASDAQ:EXAS)   Watch this stock  
Find more results for EXAS
12.84
+0.40 (3.22%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 12.27 - 12.98
52 week 6.93 - 15.60
Open 12.40
Vol / Avg. 0.00/2.94M
Mkt cap 912.56M
P/E     -
Div/yield     -
EPS -0.69
Shares 71.07M
Beta 1.32
Inst. own 90%
Apr 28, 2014
Q1 2014 EXACT Sciences Corporation Earnings Release (Estimated) Add to calendar
Mar 19, 2014
EXACT Sciences Corporation Conference Call discuss the DeeP-C clinical trial data
Mar 11, 2014
EXACT Sciences Corporation at ROTH Conference
Feb 20, 2014
Q4 2013 EXACT Sciences Corporation Earnings Conference Call
Feb 20, 2014
Q4 2013 EXACT Sciences Corporation Earnings Release
Feb 13, 2014
EXACT Sciences Corporation at Leerink Swann Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -1176.26% -1122.44%
Operating margin -1183.98% -1128.40%
EBITD margin - -1094.18%
Return on average assets -32.36% -35.95%
Return on average equity -34.86% -39.77%
Employees 87 -
CDP Score - -

Address

441 Charmany Drive
MADISON, WI 53719
United States - Map
+1-608-2845700 (Phone)
+1-608-2845701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company�s Cologuard test is a non-invasive, stool-based DNA (sDNA) screening test designed to detect deoxyribonucleic acid (DNA) markers, which in published studies have been shown to be associated with colorectal cancer. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test (FIT). The Company�s Cologuard test is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. The target sensitivity rate of its Cologuard test for cancer is equal to or greater than 85% at a specificity of 90%.

Officers and directors

Kevin T. Conroy Chairman of the Board
Age: 47
Bio & Compensation  - Reuters
William Megan Principal Financial Officer, Senior Vice President - Finance
Bio & Compensation  - Reuters
Maneesh K. Arora Chief Operating Officer
Age: 44
Bio & Compensation  - Reuters
Graham P. Lidgard Ph.D. Senior Vice President, Chief Scientific Officer
Age: 64
Bio & Compensation  - Reuters
David A. Thompson Lead Independent Director
Age: 72
Bio & Compensation  - Reuters
Thomas D. Carey Independent Director
Age: 52
Bio & Compensation  - Reuters
Sally W. Crawford Independent Director
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Daniel J. Levangie Independent Director
Age: 62
Bio & Compensation  - Reuters
Katherine S. Napier Independent Director
Age: 58
Bio & Compensation  - Reuters